Hereditary nephritis

Summary

Hereditary nephritis (MONDO:0005334) is a disease (an umbrella term covering 7 Mondo subtypes) and 1 clinical trial. A subtype of nephritis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 7 Mondo subtypes
• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	hereditary nephritis
Mondo ID	MONDO:0005334
MeSH	D009394
SNOMED CT	399340005
UMLS	C0027706
MedGen	10305
Is cancer (heuristic)	no

Also known as: familial nephritis · hereditary nephritis · nephritis, familial

Disease family

This is a subtype of nephritis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › kidney disorder › nephritis › hereditary nephritis

Related subtypes (3): interstitial nephritis, glomerulonephritis, pyelitis

Subtypes (7): IgA glomerulonephritis, Balkan nephropathy, complement factor H deficiency, C3 glomerulonephritis, karyomegalic interstitial nephritis, immunoglobulin-mediated membranoproliferative glomerulonephritis, Alport syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

4 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Bardoxolone Methyl	Phase 2
Benazepril	Phase 2
Fluvastatin	Phase 2
Valsartan	Phase 2

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06526741	Not specified	RECRUITING	ASF Alport Patient Registry